Latest research, congress highlights, and guideline interpretations
Clinical reasoning and practical insights through real-world cases.
Original research and breakthroughs in digital healthcare.
Multidisciplinary application of diabetes products and services.
This article discusses the rising burden of early‑onset diabetes in youth with rapid β‑cell deterioration. A cohort study shows CGM indices effectively predict progression to clinical T1DM among autoantibody‑positive children. TA140 >10% serves as a key high‑risk cutoff. As a non‑invasive warning radar, CGM supports early identification and intervention for pediatric high‑risk populations.
ATTD‑ASIA 2025 was held in Singapore. Russia’s policy‑driven CGM coverage greatly improved glycemic outcomes among children and adolescents with type 1 diabetes. Chinese experts illustrated multi‑scenario clinical values of CGM across general inpatients, ICU, perioperative and special populations. The hospital‑wide “virtual ward” intelligent system effectively optimized inpatient glycemic control. Integrated with AI, CGM facilitates personalized, proactive diabetes prevention, marking a shift toward precision glucose management in Asia.
The 2026 ADA guidelines elevate continuous glucose monitoring (CGM) to a core tool for diabetes management, ushering in an era of dynamic blood glucose control. It puts forward five key updates: setting personalized glycemic targets combining HbA1c and CGM indicators, expanding CGM's applicable population, optimizing suggestions for special groups, enabling early warning of hypoglycemia via CGM, and stressing that education, stable supply and skin care are essential for effective CGM application.